Autonomic Nervous SystemNCT04371757
Influence of the Autonomic Nervous System in Response to Exercise in Hypertensive Individuals
A study testing α1-adrenergic block in people with Autonomic Nervous System and Hypertension, run by Instituto de Cardiologia do Rio Grande do Sul at 1 site in Brazil.
Trial summary
Systemic arterial hypertension (SAH) has a direct association with endothelial dysfunction and major cardiovascular events. Evidence points to possible benefits of aerobic training in the endothelial function analyzed by the flow mediated dilation technique (flow mediated dilatation - FMD) in individuals with SAH. Read more about this study
- Who is it for?
- Ages 35 to 55 years
- Conditions the study is for
- Autonomic Nervous System, Hypertension
- What is being tested?
- α1-adrenergic block
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 39 participants
- Where
- 1 siteBrazil
- Study dates
- 30 Apr 2020to 23 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 55 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Clinical diagnosis of systemic arterial hypertension;
- Must be able to reality physical exercise.
Who cannot join
- Diabetes mellitus;
- Chronic renal failure;
- Body mass index ≥ 35kg/m2;
- Coronary artery disease;
- Heart failure;
- Use of beta-blocker;
Show all 9Show fewer
- Uso of alpha-blocker;
- Smoker;
- Menopause (woman).
Trial locations and contacts
1 site in 1 country.
Brazil1 site, 1 recruiting
- Recruiting
Gustavo Waclawovsky
Porto Alegre, Rio Grande do Sul, 90440-010
Gustavo Waclawovsky, PhD, 5551993649958, gwsaude@yahoo.com.br
About this study
Official title: Influence of the Autonomic Nervous System on Endothelial Function as an Acute Response to Exercise in Hypertensive Individuals: a Randomized Double-blind Protocol Study
Systemic arterial hypertension (SAH) has a direct association with endothelial dysfunction and major cardiovascular events. Evidence points to possible benefits of aerobic training in the endothelial function analyzed by the flow mediated dilation technique (flow mediated dilatation - FMD) in individuals with SAH. However, little is known about the influence of the autonomic nervous system (ANS) on the results of brachial artery FMD after different types of acute exercise in individuals with SAH. Thus, the objective of the research is to analyze the influence of the ANS on the FMD of the brachial artery of individuals with SAH after a session of aerobic (EA), resistance (ER) and combined (EC) exercise. For this, thirty-nine hypertensive individuals aged 35 to 55 years will be recruited and will be randomized to 2 sessions of AS, ER or EC. Also, within each modality, they will be randomized to α1-adrenergic block (Doxazosin 0.05 mg / kg-1) or placebo. The FMD will be performed by ultrasound 10 minutes before, as well as 10, 40 and 70 minutes after the exercise sessions and the autonomic control will be monitored (Finometer) for 10 minutes before each FMD. Arterial stiffness will also be analyzed, using the pulse wave velocity (PWV) by the Complior Analyzer. It is expected to demonstrate with this research the influence of the ANS on the FMD of the brachial artery in individuals with SAH in different physical exercises. This knowledge contributes to a better training prescription in this population.
Read the detailed description
INTRODUCTION
Endothelial dysfunction precedes atherosclerosis. Endothelial cells play an important role in the modulation of vascular angiogenesis, inflammatory responses, homeostasis, as well as vascular tone and permeability. This vascular protection function is largely attributed to nitric oxide synthase endothelial, an enzyme responsible for the production of nitric oxide (NO).
The decrease in local NO bioavailability and/or insufficient vasomotor response characterizes endothelial dysfunction; a fact evidenced in situations such as SAH, diabetes mellitus, obesity, dyslipidemia, menopause and sedentary lifestyle. The evaluation of flow-mediated dilation (FMD) of the brachial artery, although it is an indirect method to assess endothelial function, is not invasive and a large part of its result depends on NO. The findings resulting from the acute stimulus of physical exercise can also predict long-term adaptations, therefore, it has been widely used.
Within this scenario, the change in lifestyle, including regular physical exercise, is part of the recommendations of antihypertensive therapy. The most cited factors, responsible for the potential antihypertensive effect and better endothelial response to long-term exercise include reduced sympathetic activity, balance between vasodilator and vasoconstrictor factors and reduced levels of vasoconstrictor endothelin-1.
Analyzes of a resistance exercise session in the FMD demonstrated that the knee extension exercise performed with moderate intensity, as well as, with light intensity can reduce the FMD 10-30-60 minutes after the session in individuals healthy. Interestingly, the same session, when performed at high intensity, was not able to provide changes in the FMD, leading to the idea of an inverse relationship between intensity of resistance exercise and FMD response. Recently, the investigators demonstrated that an aerobic exercise session, resisted and combined (resisted and aerobic) performed in moderate intensity for 40 minutes and exclusively with lower limbs, were not able to alter the FMD of the brachial artery of individuals with SAH when analyzed 10-40-70 minutes after the sessions. These results were accompanied by maintenance of endothelial microvesicle levels and factors involved with oxidative stress. Collectively, the investigators can raise the hypothesis that other factors, such as exacerbation of sympathetic activity in untrained members, may cause vasoconstriction and redirect blood flow to trained members, consequently, competing with endothelium-dependent vasodilating activity.
Researchers have shown that α1-adrenergic blockade with Phentolamine mitigated the reduction in blood flow in the forearm, demonstrated in a placebo condition, during a manual pressure exercise session in individuals with heart failure. Still, considering that the exacerbated activation of the sympathetic nervous system has been proposed as an important factor in the development and maintenance of SAH, the investigators can hypothesize that, after a session of acute physical exercise, there is a competition between the sympathetic activity (potentiating vasoconstriction) and endothelium-dependent vasodilation capacity, in individuals with SAH.
Whereas the acute effect of different modalities of physical exercise on FMD has conflicting results in healthy and hypertensive individuals, as well as a lack of information in the hypertensive population regarding the influence of SNA activity on vessel reactivity in response to physical exercise, the investigators developed a randomized clinical trial with the primary objective of analyzing the influence of autonomic nervous system activity on the FMD of the brachial artery of individuals with SAH after acute aerobic, resisted and combined (resisted and aerobic) exercise performed exclusively with lower limbs.
METHODS
Study setting.
The study will be carried out at the Institute of Cardiology of Rio Grande do Sul/Fundação Universitária de Cardiologia under the approval of the Ethics Committee of this Institution (UP 5678/19).
Eligibility criteria.
Men and woman with SAH, between 35-55 years old who attend the services of the Institute of Cardiology of Rio Grande do Sul and do not perform regular physical exercise (≥2 sessions per week) will be selected. The sample will exclude individuals with diabetes mellitus, chronic renal failure, body mass index (BMI) ≥35kg/m2, coronary artery disease, heart failure, not to be taking antihypertensive medication, making use of beta-blocker and/or alpha-blocker, present lesions in the lower limbs that prevent the protocol, smoking and menopause (woman).
Sample size.
Researchers have compared the FMD in healthy individuals after a session of aerobic exercise performed with the condition of placebo (SD 1.13%) and α1-adrenergic block (SD 1.91%) (difference of means: 3.1%). Thus, to find a similar difference in FMD between conditions (placebo and α1-adrenergic block) after our exercise session, the investigadors calculated a total sample of 15 individuals (α=0.05 and 80% power). For the comparison in FMD between the types of exercises, the pre-exercise (SD 1.18%) and post-exercise (SD 1.91%) of the α1-adrenergic block group. To find a difference in the FMD of 1.62% (α=0.05, power 80%), the calculated total sample was 30 individuals. Assuming a loss of 30% during the protocols, the total sample was 39 individuals.
Evaluation and interventions.
The volunteers will be selected from the information described in the medical records of the IC/FUC cardiology service. The first contact with the volunteer will be made via telephone in an attempt to check, a priori, the exclusion criteria.
Step 1. The individual's first visit to the IC/FUC will take place at the Clinical Research Laboratory (LIC) and all inclusion/exclusion criteria will be resumed. After the respective signature of the Informed Consent Form, the individuals will answer a clinical questionnaire and the International Physical Activity Questionnaire. The individual's clinical blood pressure will be checked (3 blood pressure checks on the arm with the highest value).
Anthropometry will be performed at the LIC and divided into assessment of total body mass, height and waist circumference.
The exercise test will be performed on a treadmill, with the Bruce Protocol, according to the Guidelines of the Brazilian Society of Cardiology. The test will be conducted in a specialized ICF/FUC room by a qualified professional in the presence of a cardiologist. Afterwards, the maximum oxygen consumption, respiratory equivalents and maximum heart rate will be lauded (prescription of aerobic exercises).
Step 2. The second visit will be held at the LIC, with the individual fasting for 12 hours for blood collection and biochemical analysis. After blood collection, a standardized snack will be offered and volunteers will be directed to a controlled room where they will lie for 10 minutes. The evaluation of arterial stiffness will be through the carotid-femoral pulse wave velocity (PWV), with Complior Analyze equipment®. The distance between the two points is measured by an infantometer and the data on blood pressure, height, total body mass and distance between the points of the carotid and femoral arteries are entered in the Complior Analyze software to calculate the PWV.
After analyzing the PWV, the volunteers will be tested for maximum strength of the lower limbs by testing a maximum repetition (1-RM). The test will be performed at the LIC in a specific environment for physical exercise (knee extension, knee flexion, leg pressure and plantar flexion exercises). A local warm-up will be performed with 10-12 repetitions and a load relative to 30% of the estimated weight for the 1-RM test and 2:2 cadence (concentric:eccentric), controlled by a metronome. After resting for 3-5 minutes, the 1-RM test will begin. The test will be interrupted to adjust the load when the individual performs more than 1-repetition or when he was unable to overcome the proposed load. When further attempts are required, a 5-minute rest period is allowed. The weight at which the individual performs only one repetition will be determined as 1-RM.
Step 3-4. To analyze the influence of the SNS on the FMD in response to physical exercise sessions, the α1-adrenergic blocking described in the literature will be used. Considering the interruption of the commercialization of the drug prazosin in Brazil, it will be replaced by its analogue doxazosin. Briefly, 90 minutes before starting the exercise protocol, individuals will be offered a capsule containing placebo (microcrystalline cellulose) or α1-adrenoreceptor blocker (Doxazosin 0.05 mg.kg-1 body weight) and will be instructed to lie down. A researcher collaborating in the group and blinded to the type of physical exercise, will be responsible for making the capsules available to the individual on the day of the session, according to previous randomization.
Evaluation of endothelial function: the evaluation of endothelial function will be performed by ultrasound using the FMD technique, as previously described. Initially, the speed of blood flow and the diameter of the brachial artery will be evaluated, simultaneously, in the volunteer's right arm, in a quiet, darkened room with controlled temperature (23-24°C) of the LIC, by a single qualified investigator and blinded to the condition. The initial blood pressure (left arm), resting heart rate, blood flow velocity and the diameter of the brachial artery will be evaluated after resting for 10-15 minutes in a supine position, with the subject's arm extended and positioned at an angle of ~40° of the trunk. The evaluation will take place 10 minutes before the exercise session, as well as 10-40-70 minutes after the exercise session.
To analyze the FMD of the brachial artery, individuals should be fasting for ≥6 hours, medicated for SAH. A rapid deflation cuff will be placed around the forearm 5 cm distal to the antecubital fossa and the image of the brachial artery will be obtained in the distal third of the arm in B-mode using a linear multi-frequency transducer (12MHz) connected to a high resolution Doppler Ultrasound system. The sample volume will be adjusted to cover the width of the vessel and an insonation angle of 60° will be used. Baseline diameters will be recorded for 1 minute, before the forearm cuff is inflated at 50 mmHg above the SBP, for 5 minutes. The recording of the images will be resumed 30 seconds before the deflation of the cuff and maintained for 3 minutes after deflation. The video signal of the Doppler Ultrasound will be recorded in real time by a USB video card and saved for offline analysis. The analysis of blood flow velocity and brachial artery diameter will be performed using edge detection and wall tracking software (CardiovasculareSuit™; Pisa, Italy). From the synchronized blood flow velocity data and the brachial artery diameter, the blood flow will be calculated at 30Hz. The FMD will be calculated as the percentage change in the peak diameter after deflating the cuff from the reference diameter (baseline).
Nervous system: the assessment of the ANS will be performed through the variability of heart rate and blood pressure, as already described in the literature. The data will be collected through the pressure wave acquisition system in a continuous and non-invasive way by the Finometer® system. For this, a cuffing will be installed on the middle finger (right hand) coupled to an analog-to-digital signal converter. The frequency of sampling the signals will be acquired continuously at 1000 Hz, after resting the individual (lying down for 10 minutes) and before the FMD analysis.
The collected data will be saved in the BeatsScope® and LabChart® software for analysis of blood pressure variability (BPV) histograms and pulse interval series (RR-interval) for spectral power analysis (heart rate variability, HRV). The pulse interval(PI) will be calculated as the difference between the start and end points of the cycle. The analysis of HRV and BPV in the time domain, such as the spectral composition (fast Fourier transform) will be performed using the CardioSeries® software (after removing transient and discrepant elements). The spectral bands for evaluation: very low frequency (VLF, 0.007-0.04Hz), low frequency (LF, 0.04-0.15Hz), high frequency (HF, 0.15-0.4Hz) and total power (TP, VLF+LF+HF). Spontaneous baroreflex sensitivity (SBE) will be inferred by the square root of (LF/HRV m2)/(LF/BPV m2).
The physical exercise sessions will be carried out in two visits, always in the afternoon (1:00 pm) and in random order for placebo or α1-adrenergic block. Moderate fasting (6 hours) will be required and sessions should have intervals of at least 5-7 days. The exercise sessions will be: aerobic, resistance and combined, previously published by our group.
The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
Statistical analysis.
The normality of the data will be assessed by Shapiro-Wilk. Values will be presented as mean ± standard deviation or mediated and 95% CI, according to the distribution of variables. One-way ANOVA will be used for prior comparisons of baseline data between groups. The multivariate analysis of the data will be performed using the GEE for repeated measures with Bonferroni's post-hoc. The evaluation of possible correlations between variables will be performed using Pearson or Spearman tests. Statistical analysis: SPSS 24.0, p-value <0.05.
- Conditions
- Autonomic Nervous System, Hypertension
- Being tested
- α1-adrenergic block, Placebo
- Keywords
- Endothelium, Physical Exercise
- Medical subject headings
- Hypertension, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
α1-adrenergic blockDrug
Also called Doxazosin
Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
PlaceboOther
Also called Microcrystalline cellulose
Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
| Study group | Role | What they receive |
|---|---|---|
| Aerobic exercise session | Experimental | The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end. Receives: Drug: α1-adrenergic block; Other: Placebo |
| Resistance exercise session | Experimental | The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise. Receives: Drug: α1-adrenergic block; Other: Placebo |
| Combined exercise session | Experimental | The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises. Receives: Drug: α1-adrenergic block; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in the endothelial function of hypertensive individuals after a session of aerobic exercise, resistance exercise and combined exercise in α1-adrenoreceptor blocker and placebo condition.
The method of assessing the flow-mediated dilation (FMD) of the brachial artery by ultrasonography is an indirect method to assess endothelial function. To analyze the FMD of the brachial artery a rapid deflation cuff will be placed around the forearm 5 cm distal to the antecubital fossa and the image of the brachial artery will be obtained in the distal third of the arm. Baseline diameters will be recorded for 1 minute, before the forearm cuff is inflated at 50 mmHg above the SBP, for 5 minutes. The recording of the images will be resumed 30 seconds before the deflation of the cuff and maintained for 3 minutes after deflation. The video signal of the Doppler Ultrasound will be recorded in real time by a USB video card and saved for offline analysis. The analysis of diameter will be performed using edge detection and wall tracking software. The FMD will be calculated as the percentage change in the peak diameter after deflating the cuff from the baseline diameter.
Measured: Ten minutes before the exercise session and 10, 40 and 70 minutes after the exercise session.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2020
- Study start30 Apr 2020 (estimated)
- Primary completion20 Dec 2020 (estimated)
- Study completion23 Dec 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (25)Papers the sponsor has linked to this study.
- Other trials for Autonomic Nervous SystemStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomization for exercise interventions, as well as placebo or α1-adrenergic, will be performed using a computer program containing the coded distribution. The randomization of the subjects will be characterized as simple and divided into two parts; (A) directed to the three arms of exercise (aerobica exercise, resistido exercise and combinade exercise) and (B) the order in relation to the placebo or α1-adrenergic block.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 39 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Instituto de Cardiologia do Rio Grande do Sul
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04371757
- Sponsor's protocol ID
- Autonomic nervous system
- Status last verified
- Apr 2020
- First submitted
- 16 Apr 2020
- Last updated
- 1 May 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gimbrone MA Jr, Garcia-Cardena G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016 Feb 19;118(4):620-36. doi: 10.1161/CIRCRESAHA.115.306301.
PubMed 26892962Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017 Jan;219(1):22-96. doi: 10.1111/apha.12646. Epub 2016 Jan 25.
PubMed 26706498Iantorno M, Campia U, Di Daniele N, Nistico S, Forleo GB, Cardillo C, Tesauro M. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014 Apr-Jun;28(2):169-76.
PubMed 25001649Lind L. Lipids and endothelium-dependent vasodilation--a review. Lipids. 2002 Jan;37(1):1-15. doi: 10.1007/s11745-002-0858-6.
PubMed 11876256ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013 Oct;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c. No abstract available.
PubMed 24107724Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. J Am Soc Hypertens. 2016 May;10(5):457-66. doi: 10.1016/j.jash.2016.02.015. Epub 2016 Mar 4.
PubMed 27052349Ghorayeb N, Stein R, Daher DJ, Silveira ADD, Ritt LEF, Santos DFPD, Sierra APR, Herdy AH, Araujo CGS, Colombo CSSS, Kopiler DA, Lacerda FFR, Lazzoli JK, Matos LDNJ, Leitao MB, Francisco RC, Alo ROB, Timerman S, Carvalho T, Garcia TG. The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019. Arq Bras Cardiol. 2019 Mar;112(3):326-368. doi: 10.5935/abc.20190048. No abstract available.
PubMed 30916199Brandao AA, Amodeo C, Alcantara C, Barbosa E, Nobre F, Pinto F, Vilela-Martin JF, Bastos JM, Yugar-Toledo JC, Mota-Gomes MA, Neves MF, Malachias MV, Rodrigues MC, Passarelli O Junior, Jardim PC, Cunha PG, Povoa R, Fonseca T, Dias VP, Barroso WS, Oigman W. I Luso-Brazilian Positioning on Central Arterial Pressure. Arq Bras Cardiol. 2017 Feb;108(2):100-108. doi: 10.5935/abc.20170011. Epub 2017 Feb 13. No abstract available.
PubMed 28327876Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, Zock PL, Taddei S, Deanfield JE, Luscher T, Green DJ, Ghiadoni L. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534-2547. doi: 10.1093/eurheartj/ehz350.
PubMed 31211361Soloviev MA, Kulakova NV, Semiglazova TA, Borodulina EV, Udut VV. Correction of endothelial dysfunction in patients with arterial hypertension. Bull Exp Biol Med. 2011 Jun;151(2):183-5. doi: 10.1007/s10517-011-1284-1.
PubMed 22238745Abebe W, Mozaffari M. Endothelial dysfunction in diabetes: potential application of circulating markers as advanced diagnostic and prognostic tools. EPMA J. 2010 Mar;1(1):32-45. doi: 10.1007/s13167-010-0012-7. Epub 2010 Mar 10.
PubMed 23199039Kublickiene K, Fu XD, Svedas E, Landgren BM, Genazzani AR, Simoncini T. Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab. 2008 May;93(5):1874-83. doi: 10.1210/jc.2007-2651. Epub 2008 Mar 4.
PubMed 18319309Pahkala K, Heinonen OJ, Simell O, Viikari JS, Ronnemaa T, Niinikoski H, Raitakari OT. Association of physical activity with vascular endothelial function and intima-media thickness. Circulation. 2011 Nov 1;124(18):1956-63. doi: 10.1161/CIRCULATIONAHA.111.043851. Epub 2011 Oct 3.
PubMed 21969011Green DJ, Dawson EA, Groenewoud HM, Jones H, Thijssen DH. Is flow-mediated dilation nitric oxide mediated?: A meta-analysis. Hypertension. 2014 Feb;63(2):376-82. doi: 10.1161/HYPERTENSIONAHA.113.02044. Epub 2013 Nov 25.
PubMed 24277765Dawson EA, Cable NT, Green DJ, Thijssen DHJ. Do acute effects of exercise on vascular function predict adaptation to training? Eur J Appl Physiol. 2018 Mar;118(3):523-530. doi: 10.1007/s00421-017-3724-8. Epub 2017 Dec 12.
PubMed 29234916
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Influence of the Autonomic Nervous System on Endothelial Function as an Acute Response to Exercise in Hypertensive Individuals: a Randomized Double-blind Protocol Study
- ClinicalTrials.gov ID
- NCT04371757
- Acronym / sponsor ID
- Autonomic nervous system
- Conditions
- Autonomic Nervous System, Hypertension
- Keywords
- Endothelium, Physical Exercise
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 39 participants (estimated)
- Lead sponsor
- Instituto de Cardiologia do Rio Grande do SulUniversity, hospital or other
- Study start
- 30 Apr 2020 (estimated)
- Primary completion
- 20 Dec 2020 (estimated)
- Study completion
- 23 Dec 2021 (estimated)
- First posted
- 1 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Systemic arterial hypertension (SAH) has a direct association with endothelial dysfunction and major cardiovascular events. Evidence points to possible benefits of aerobic training in the endothelial function analyzed by the flow mediated dilation technique (flow mediated dilatation - FMD) in individuals with SAH. However, little is known about the influence of the autonomic nervous system (ANS) on the results of brachial artery FMD after different types of acute exercise in individuals with SAH. Thus, the objective of the research is to analyze the influence of the ANS on the FMD of the brachial artery of individuals with SAH after a session of aerobic (EA), resistance (ER) and combined (EC) exercise. For this, thirty-nine hypertensive individuals aged 35 to 55 years will be recruited and will be randomized to 2 sessions of AS, ER or EC. Also, within each modality, they will be randomized to α1-adrenergic block (Doxazosin 0.05 mg / kg-1) or placebo. The FMD will be performed by ultrasound 10 minutes before, as well as 10, 40 and 70 minutes after the exercise sessions and the autonomic control will be monitored (Finometer) for 10 minutes before each FMD. Arterial stiffness will also be analyzed, using the pulse wave velocity (PWV) by the Complior Analyzer. It is expected to demonstrate with this research the influence of the ANS on the FMD of the brachial artery in individuals with SAH in different physical exercises. This knowledge contributes to a better training prescription in this population.
Detailed description
INTRODUCTION
Endothelial dysfunction precedes atherosclerosis. Endothelial cells play an important role in the modulation of vascular angiogenesis, inflammatory responses, homeostasis, as well as vascular tone and permeability. This vascular protection function is largely attributed to nitric oxide synthase endothelial, an enzyme responsible for the production of nitric oxide (NO).
The decrease in local NO bioavailability and/or insufficient vasomotor response characterizes endothelial dysfunction; a fact evidenced in situations such as SAH, diabetes mellitus, obesity, dyslipidemia, menopause and sedentary lifestyle. The evaluation of flow-mediated dilation (FMD) of the brachial artery, although it is an indirect method to assess endothelial function, is not invasive and a large part of its result depends on NO. The findings resulting from the acute stimulus of physical exercise can also predict long-term adaptations, therefore, it has been widely used.
Within this scenario, the change in lifestyle, including regular physical exercise, is part of the recommendations of antihypertensive therapy. The most cited factors, responsible for the potential antihypertensive effect and better endothelial response to long-term exercise include reduced sympathetic activity, balance between vasodilator and vasoconstrictor factors and reduced levels of vasoconstrictor endothelin-1.
Analyzes of a resistance exercise session in the FMD demonstrated that the knee extension exercise performed with moderate intensity, as well as, with light intensity can reduce the FMD 10-30-60 minutes after the session in individuals healthy. Interestingly, the same session, when performed at high intensity, was not able to provide changes in the FMD, leading to the idea of an inverse relationship between intensity of resistance exercise and FMD response. Recently, the investigators demonstrated that an aerobic exercise session, resisted and combined (resisted and aerobic) performed in moderate intensity for 40 minutes and exclusively with lower limbs, were not able to alter the FMD of the brachial artery of individuals with SAH when analyzed 10-40-70 minutes after the sessions. These results were accompanied by maintenance of endothelial microvesicle levels and factors involved with oxidative stress. Collectively, the investigators can raise the hypothesis that other factors, such as exacerbation of sympathetic activity in untrained members, may cause vasoconstriction and redirect blood flow to trained members, consequently, competing with endothelium-dependent vasodilating activity.
Researchers have shown that α1-adrenergic blockade with Phentolamine mitigated the reduction in blood flow in the forearm, demonstrated in a placebo condition, during a manual pressure exercise session in individuals with heart failure. Still, considering that the exacerbated activation of the sympathetic nervous system has been proposed as an important factor in the development and maintenance of SAH, the investigators can hypothesize that, after a session of acute physical exercise, there is a competition between the sympathetic activity (potentiating vasoconstriction) and endothelium-dependent vasodilation capacity, in individuals with SAH.
Whereas the acute effect of different modalities of physical exercise on FMD has conflicting results in healthy and hypertensive individuals, as well as a lack of information in the hypertensive population regarding the influence of SNA activity on vessel reactivity in response to physical exercise, the investigators developed a randomized clinical trial with the primary objective of analyzing the influence of autonomic nervous system activity on the FMD of the brachial artery of individuals with SAH after acute aerobic, resisted and combined (resisted and aerobic) exercise performed exclusively with lower limbs.
METHODS
Study setting.
The study will be carried out at the Institute of Cardiology of Rio Grande do Sul/Fundação Universitária de Cardiologia under the approval of the Ethics Committee of this Institution (UP 5678/19).
Eligibility criteria.
Men and woman with SAH, between 35-55 years old who attend the services of the Institute of Cardiology of Rio Grande do Sul and do not perform regular physical exercise (≥2 sessions per week) will be selected. The sample will exclude individuals with diabetes mellitus, chronic renal failure, body mass index (BMI) ≥35kg/m2, coronary artery disease, heart failure, not to be taking antihypertensive medication, making use of beta-blocker and/or alpha-blocker, present lesions in the lower limbs that prevent the protocol, smoking and menopause (woman).
Sample size.
Researchers have compared the FMD in healthy individuals after a session of aerobic exercise performed with the condition of placebo (SD 1.13%) and α1-adrenergic block (SD 1.91%) (difference of means: 3.1%). Thus, to find a similar difference in FMD between conditions (placebo and α1-adrenergic block) after our exercise session, the investigadors calculated a total sample of 15 individuals (α=0.05 and 80% power). For the comparison in FMD between the types of exercises, the pre-exercise (SD 1.18%) and post-exercise (SD 1.91%) of the α1-adrenergic block group. To find a difference in the FMD of 1.62% (α=0.05, power 80%), the calculated total sample was 30 individuals. Assuming a loss of 30% during the protocols, the total sample was 39 individuals.
Evaluation and interventions.
The volunteers will be selected from the information described in the medical records of the IC/FUC cardiology service. The first contact with the volunteer will be made via telephone in an attempt to check, a priori, the exclusion criteria.
Step 1. The individual's first visit to the IC/FUC will take place at the Clinical Research Laboratory (LIC) and all inclusion/exclusion criteria will be resumed. After the respective signature of the Informed Consent Form, the individuals will answer a clinical questionnaire and the International Physical Activity Questionnaire. The individual's clinical blood pressure will be checked (3 blood pressure checks on the arm with the highest value).
Anthropometry will be performed at the LIC and divided into assessment of total body mass, height and waist circumference.
The exercise test will be performed on a treadmill, with the Bruce Protocol, according to the Guidelines of the Brazilian Society of Cardiology. The test will be conducted in a specialized ICF/FUC room by a qualified professional in the presence of a cardiologist. Afterwards, the maximum oxygen consumption, respiratory equivalents and maximum heart rate will be lauded (prescription of aerobic exercises).
Step 2. The second visit will be held at the LIC, with the individual fasting for 12 hours for blood collection and biochemical analysis. After blood collection, a standardized snack will be offered and volunteers will be directed to a controlled room where they will lie for 10 minutes. The evaluation of arterial stiffness will be through the carotid-femoral pulse wave velocity (PWV), with Complior Analyze equipment®. The distance between the two points is measured by an infantometer and the data on blood pressure, height, total body mass and distance between the points of the carotid and femoral arteries are entered in the Complior Analyze software to calculate the PWV.
After analyzing the PWV, the volunteers will be tested for maximum strength of the lower limbs by testing a maximum repetition (1-RM). The test will be performed at the LIC in a specific environment for physical exercise (knee extension, knee flexion, leg pressure and plantar flexion exercises). A local warm-up will be performed with 10-12 repetitions and a load relative to 30% of the estimated weight for the 1-RM test and 2:2 cadence (concentric:eccentric), controlled by a metronome. After resting for 3-5 minutes, the 1-RM test will begin. The test will be interrupted to adjust the load when the individual performs more than 1-repetition or when he was unable to overcome the proposed load. When further attempts are required, a 5-minute rest period is allowed. The weight at which the individual performs only one repetition will be determined as 1-RM.
Step 3-4. To analyze the influence of the SNS on the FMD in response to physical exercise sessions, the α1-adrenergic blocking described in the literature will be used. Considering the interruption of the commercialization of the drug prazosin in Brazil, it will be replaced by its analogue doxazosin. Briefly, 90 minutes before starting the exercise protocol, individuals will be offered a capsule containing placebo (microcrystalline cellulose) or α1-adrenoreceptor blocker (Doxazosin 0.05 mg.kg-1 body weight) and will be instructed to lie down. A researcher collaborating in the group and blinded to the type of physical exercise, will be responsible for making the capsules available to the individual on the day of the session, according to previous randomization.
Evaluation of endothelial function: the evaluation of endothelial function will be performed by ultrasound using the FMD technique, as previously described. Initially, the speed of blood flow and the diameter of the brachial artery will be evaluated, simultaneously, in the volunteer's right arm, in a quiet, darkened room with controlled temperature (23-24°C) of the LIC, by a single qualified investigator and blinded to the condition. The initial blood pressure (left arm), resting heart rate, blood flow velocity and the diameter of the brachial artery will be evaluated after resting for 10-15 minutes in a supine position, with the subject's arm extended and positioned at an angle of ~40° of the trunk. The evaluation will take place 10 minutes before the exercise session, as well as 10-40-70 minutes after the exercise session.
To analyze the FMD of the brachial artery, individuals should be fasting for ≥6 hours, medicated for SAH. A rapid deflation cuff will be placed around the forearm 5 cm distal to the antecubital fossa and the image of the brachial artery will be obtained in the distal third of the arm in B-mode using a linear multi-frequency transducer (12MHz) connected to a high resolution Doppler Ultrasound system. The sample volume will be adjusted to cover the width of the vessel and an insonation angle of 60° will be used. Baseline diameters will be recorded for 1 minute, before the forearm cuff is inflated at 50 mmHg above the SBP, for 5 minutes. The recording of the images will be resumed 30 seconds before the deflation of the cuff and maintained for 3 minutes after deflation. The video signal of the Doppler Ultrasound will be recorded in real time by a USB video card and saved for offline analysis. The analysis of blood flow velocity and brachial artery diameter will be performed using edge detection and wall tracking software (CardiovasculareSuit™; Pisa, Italy). From the synchronized blood flow velocity data and the brachial artery diameter, the blood flow will be calculated at 30Hz. The FMD will be calculated as the percentage change in the peak diameter after deflating the cuff from the reference diameter (baseline).
Nervous system: the assessment of the ANS will be performed through the variability of heart rate and blood pressure, as already described in the literature. The data will be collected through the pressure wave acquisition system in a continuous and non-invasive way by the Finometer® system. For this, a cuffing will be installed on the middle finger (right hand) coupled to an analog-to-digital signal converter. The frequency of sampling the signals will be acquired continuously at 1000 Hz, after resting the individual (lying down for 10 minutes) and before the FMD analysis.
The collected data will be saved in the BeatsScope® and LabChart® software for analysis of blood pressure variability (BPV) histograms and pulse interval series (RR-interval) for spectral power analysis (heart rate variability, HRV). The pulse interval(PI) will be calculated as the difference between the start and end points of the cycle. The analysis of HRV and BPV in the time domain, such as the spectral composition (fast Fourier transform) will be performed using the CardioSeries® software (after removing transient and discrepant elements). The spectral bands for evaluation: very low frequency (VLF, 0.007-0.04Hz), low frequency (LF, 0.04-0.15Hz), high frequency (HF, 0.15-0.4Hz) and total power (TP, VLF+LF+HF). Spontaneous baroreflex sensitivity (SBE) will be inferred by the square root of (LF/HRV m2)/(LF/BPV m2).
The physical exercise sessions will be carried out in two visits, always in the afternoon (1:00 pm) and in random order for placebo or α1-adrenergic block. Moderate fasting (6 hours) will be required and sessions should have intervals of at least 5-7 days. The exercise sessions will be: aerobic, resistance and combined, previously published by our group.
The aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end.
The resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise.
The combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises.
Statistical analysis.
The normality of the data will be assessed by Shapiro-Wilk. Values will be presented as mean ± standard deviation or mediated and 95% CI, according to the distribution of variables. One-way ANOVA will be used for prior comparisons of baseline data between groups. The multivariate analysis of the data will be performed using the GEE for repeated measures with Bonferroni's post-hoc. The evaluation of possible correlations between variables will be performed using Pearson or Spearman tests. Statistical analysis: SPSS 24.0, p-value <0.05.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
- Model description
- Randomization for exercise interventions, as well as placebo or α1-adrenergic, will be performed using a computer program containing the coded distribution. The randomization of the subjects will be characterized as simple and divided into two parts; (A) directed to the three arms of exercise (aerobica exercise, resistido exercise and combinade exercise) and (B) the order in relation to the placebo or α1-adrenergic block.
| Arm | Type | Receives |
|---|---|---|
| Aerobic exercise session | Experimental | Drug: α1-adrenergic block, Other: PlaceboThe aerobic exercise session will be performed on a horizontal cycle ergometer. A warm-up will be performed (5 minutes), followed by 40 minutes with moderate intensity (60% HRreserve) and controlled by a heart rate monitor, as well as the subjective effort scale (Borg 6 to 20 points). Blood pressure, heart rate and the Borg scale will be assessed at the beginning of aerobic exercise and every 5 minutes until the end. |
| Resistance exercise session | Experimental | Drug: α1-adrenergic block, Other: PlaceboThe resistance exercise session will be structured with knee extension, knee flexion, leg pressure and plantar flexion, in a station with guided weights, with 4x12 repetitions and 60% intensity of 1-RM; the cadence will be adjusted to 2:2 (concentric: eccentric) and controlled by a metronome. The rest between sets and exercises will be 90 seconds (total duration: 40 minutes). Blood pressure, heart rate and Borg scale will be recorded at the beginning and at the end of the 4th series of each exercise. |
| Combined exercise session | Experimental | Drug: α1-adrenergic block, Other: PlaceboThe combined exercise session will be structured with 20 minutes of resistance exercise + 20 minutes of aerobic exercise, as already described, except that the resistance exercises will have 2 sets of each exercise. As with other sessions, blood pressure, heart rate and the Borg scale will be assessed at the beginning and end of the second series of resistance exercise, as well as at the beginning and every 5 minutes of aerobic exercise up to 15 minutes after end of exercises. |
Who may qualify
- Ages
- 35 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Clinical diagnosis of systemic arterial hypertension;
- Must be able to reality physical exercise.
Key exclusion criteria (9 listed)
- Diabetes mellitus;
- Chronic renal failure;
- Body mass index ≥ 35kg/m2;
- Coronary artery disease;
- Heart failure;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| α1-adrenergic blockAlso: DoxazosinNinety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy. | Drug | Aerobic exercise session, Combined exercise session, Resistance exercise session |
| PlaceboAlso: Microcrystalline celluloseNinety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy. | Other | Aerobic exercise session, Combined exercise session, Resistance exercise session |
Primary outcome
Changes in the endothelial function of hypertensive individuals after a session of aerobic exercise, resistance exercise and combined exercise in α1-adrenoreceptor blocker and placebo condition.
Time frame: Ten minutes before the exercise session and 10, 40 and 70 minutes after the exercise session.
The method of assessing the flow-mediated dilation (FMD) of the brachial artery by ultrasonography is an indirect method to assess endothelial function. To analyze the FMD of the brachial artery a rapid deflation cuff will be placed around the forearm 5 cm distal to the antecubital fossa and the image of the brachial artery will be obtained in the distal third of the arm. Baseline diameters will be recorded for 1 minute, before the forearm cuff is inflated at 50 mmHg above the SBP, for 5 minutes. The recording of the images will be resumed 30 seconds before the deflation of the cuff and maintained for 3 minutes after deflation. The video signal of the Doppler Ultrasound will be recorded in real time by a USB video card and saved for offline analysis. The analysis of diameter will be performed using edge detection and wall tracking software. The FMD will be calculated as the percentage change in the peak diameter after deflating the cuff from the baseline diameter.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2020.
- Background: PubMed 26892962Gimbrone MA Jr, Garcia-Cardena G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016 Feb 19;118(4):620-36. doi: 10.1161/CIRCRESAHA.115.306301.
- Background: PubMed 26706498Vanhoutte PM, Shimokawa H, Feletou M, Tang EH. Endothelial dysfunction and vascular disease - a 30th anniversary update. Acta Physiol (Oxf). 2017 Jan;219(1):22-96. doi: 10.1111/apha.12646. Epub 2016 Jan 25.
- Background: PubMed 25001649Iantorno M, Campia U, Di Daniele N, Nistico S, Forleo GB, Cardillo C, Tesauro M. Obesity, inflammation and endothelial dysfunction. J Biol Regul Homeost Agents. 2014 Apr-Jun;28(2):169-76.
- Background: PubMed 11876256Lind L. Lipids and endothelium-dependent vasodilation--a review. Lipids. 2002 Jan;37(1):1-15. doi: 10.1007/s11745-002-0858-6.
- Background: PubMed 24107724ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013 Oct;31(10):1925-38. doi: 10.1097/HJH.0b013e328364ca4c. No abstract available.
- Background: PubMed 27052349Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. J Am Soc Hypertens. 2016 May;10(5):457-66. doi: 10.1016/j.jash.2016.02.015. Epub 2016 Mar 4.
- Background: PubMed 30916199Ghorayeb N, Stein R, Daher DJ, Silveira ADD, Ritt LEF, Santos DFPD, Sierra APR, Herdy AH, Araujo CGS, Colombo CSSS, Kopiler DA, Lacerda FFR, Lazzoli JK, Matos LDNJ, Leitao MB, Francisco RC, Alo ROB, Timerman S, Carvalho T, Garcia TG. The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019. Arq Bras Cardiol. 2019 Mar;112(3):326-368. doi: 10.5935/abc.20190048. No abstract available.
- Background: PubMed 28327876Brandao AA, Amodeo C, Alcantara C, Barbosa E, Nobre F, Pinto F, Vilela-Martin JF, Bastos JM, Yugar-Toledo JC, Mota-Gomes MA, Neves MF, Malachias MV, Rodrigues MC, Passarelli O Junior, Jardim PC, Cunha PG, Povoa R, Fonseca T, Dias VP, Barroso WS, Oigman W. I Luso-Brazilian Positioning on Central Arterial Pressure. Arq Bras Cardiol. 2017 Feb;108(2):100-108. doi: 10.5935/abc.20170011. Epub 2017 Feb 13. No abstract available.
- Background: PubMed 31211361Thijssen DHJ, Bruno RM, van Mil ACCM, Holder SM, Faita F, Greyling A, Zock PL, Taddei S, Deanfield JE, Luscher T, Green DJ, Ghiadoni L. Expert consensus and evidence-based recommendations for the assessment of flow-mediated dilation in humans. Eur Heart J. 2019 Aug 7;40(30):2534-2547. doi: 10.1093/eurheartj/ehz350.
- Results publication: PubMed 22238745Soloviev MA, Kulakova NV, Semiglazova TA, Borodulina EV, Udut VV. Correction of endothelial dysfunction in patients with arterial hypertension. Bull Exp Biol Med. 2011 Jun;151(2):183-5. doi: 10.1007/s10517-011-1284-1.
- Results publication: PubMed 23199039Abebe W, Mozaffari M. Endothelial dysfunction in diabetes: potential application of circulating markers as advanced diagnostic and prognostic tools. EPMA J. 2010 Mar;1(1):32-45. doi: 10.1007/s13167-010-0012-7. Epub 2010 Mar 10.
- Results publication: PubMed 18319309Kublickiene K, Fu XD, Svedas E, Landgren BM, Genazzani AR, Simoncini T. Effects in postmenopausal women of estradiol and medroxyprogesterone alone and combined on resistance artery function and endothelial morphology and movement. J Clin Endocrinol Metab. 2008 May;93(5):1874-83. doi: 10.1210/jc.2007-2651. Epub 2008 Mar 4.
- Individual participant dataSharing planned: No
Related trials for Autonomic Nervous System
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Enrolling by invitationPhase 4
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Complex Regional Pain Syndrome, Chronic Pain
Active, not recruitingPhase 2
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Multiple System Atrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing α1-adrenergic block in people with Autonomic Nervous System and Hypertension, run by Instituto de Cardiologia do Rio Grande do Sul at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Gustavo Waclawovsky, PhD (555132354070, gwsaude@yahoo.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in the endothelial function of hypertensive individuals after a session of aerobic exercise, resistance exercise and combined exercise in α1-adrenoreceptor blocker and placebo condition. (time frame: Ten minutes before the exercise session and 10, 40 and 70 minutes after the exercise session.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04371757, which also lists 25 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2020.